161 related articles for article (PubMed ID: 20524305)
1. Bortezomib in kidney transplant recipients with antibody mediated rejection: three case reports.
Wong W; Lee RA; Saidman SL; Smith RN; Zorn E
Clin Transpl; 2009; ():401-5. PubMed ID: 20524305
[TBL] [Abstract][Full Text] [Related]
2. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.
Hamawi K; Heilman RL; Mazur MJ; Chakkera HA; Mulligan DC; Moss AA; Mekeel KL; Reddy KS
Clin Transpl; 2009; ():407-14. PubMed ID: 20524306
[No Abstract] [Full Text] [Related]
3. Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases.
Mai HL; Cesbron A; Brouard S; Blanchol G; Cantarovich D; Dantal J; Hourmant M; Lino M; Meurette A; Gosselin M; Abbadie O; Soulillou JP; Giral M
Clin Transpl; 2009; ():361-8. PubMed ID: 20524299
[No Abstract] [Full Text] [Related]
4. Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.
Al Meshari K
Clin Transpl; 2009; ():385-6. PubMed ID: 20524302
[No Abstract] [Full Text] [Related]
5. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC.
Pavlakis M
Clin Transpl; 2009; ():343-5. PubMed ID: 20524296
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
[TBL] [Abstract][Full Text] [Related]
7. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
Al Meshari K; Pall A; Elgamal H; Alzayer F; Altalhi M
Clin Transpl; 2010; ():383-90. PubMed ID: 21696055
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report.
Schwaiger E; Regele H; Wahrmann M; Werzowa J; Haidbauer B; Schmidt A; Böhmig GA
Clin Transpl; 2010; ():391-6. PubMed ID: 21696056
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib as rescue therapy for antibody mediated rejection: a single-center experience.
Hardinger KL; Alford K; Murillo D
Clin Transpl; 2010; ():429-36. PubMed ID: 21696060
[TBL] [Abstract][Full Text] [Related]
11. Use of bortezomib for prevention and treatment of rejection in sensitized patients.
Hartono C; Lubetzky M; Aull MJ; Saal S; Figueiro J; Kapur S; Dadhania D
Clin Transpl; 2009; ():499-503. PubMed ID: 20524323
[TBL] [Abstract][Full Text] [Related]
12. Rescue therapy for early antibody mediated rejection with a proteasome inhibitor: a case report.
Manitpisitkul W; Wilson N; Cooper M; Gurk-Turner C; Hurley H; Rasetto F; KuKuruga D; Barth RN; Philosophe B
Clin Transpl; 2009; ():461-3. PubMed ID: 20524315
[No Abstract] [Full Text] [Related]
13. A summary of bortezomib use in transplantation across 29 centers.
Everly MJ
Clin Transpl; 2009; ():323-37. PubMed ID: 20524294
[TBL] [Abstract][Full Text] [Related]
14. Failure of bortezomib to cure acute antibody-mediated rejection in a non-compliant renal transplant patient.
Ryckewaert A; Allain-Launay E; Moreau A; Blancho G; Cesbron A; Blin N; Roussey G
Pediatr Transplant; 2013 Sep; 17(6):E131-6. PubMed ID: 23834525
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib use in chronic antibody-mediated allograft dysfunction: updates and additional cases.
Cooper JE; Wiseman AC; Chan L
Clin Transpl; 2010; ():415-20. PubMed ID: 21698838
[No Abstract] [Full Text] [Related]
16. Bortezomib in kidney transplant desensitization: a case report.
Raghavan R; Jeroudi A; Achkar K; Suki W; Gaber AO; Knight R; Land G; Dilioglou S; Patel S; Abdellatif A
Clin Transpl; 2009; ():339-42. PubMed ID: 20524295
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?
Lee I; Constantinescu S; Gillespie A; Swami A; Birkenbach M; Leech S; Silva P; Karachristos A; Daller JA; Sifontis NM
Clin Transpl; 2009; ():425-9. PubMed ID: 20524309
[No Abstract] [Full Text] [Related]
18. Rescue therapy for acute antibody mediated rejection with a proteosome inhibitor after kidney transplantation.
Manitpisitkul W; Wilson NS; Philosophe B; Cooper M; Drachenberg C; Kukuruga D; Nogueira J; Haririan A
Clin Transpl; 2010; ():421-8. PubMed ID: 21698839
[No Abstract] [Full Text] [Related]
19. Bortezomib for acute humoral rejection in two repeat transplant recipients.
Hardinger KL; Alford K; Murillo D
Clin Transpl; 2009; ():479-83. PubMed ID: 20524319
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.
Sureshkumar KK; Hussain SM; Marcus RJ; Ko TY; Khan AS; Tom K; Vivas CA; Parris G; Jasnosz KM; Thai NL
Clin Nephrol; 2012 Mar; 77(3):246-53. PubMed ID: 22377258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]